eCommerce

Diet modification reduces fatal disease. Study links gut microbiome and prostate cancer

Researchers from the American Hospital Cleveland Clinic have revealed for the first time that the gut microbiome (the diverse communities of microorganisms that live in the intestine and help some of them digest food) is linked to prostate cancer, suggesting that intervention to modify the diet may help reduce the risk of this deadly disease. .

The results of the study were published in the journal Cancer epidemiology, (Cancer Epidemiology, Biomarkers & Prevention) specialized in cancer science, its vital signs and its prevention.

The team leader, who worked on the study, Dr. Neama Sharifi, said the findings from the team’s analysis of nearly 700 patient records may have clinical implications for prostate cancer diagnosis and prevention. This requires further research on this topic.

Dr. Sharifi, director of the Genitourinary Tumor Research Center at the Cleveland Clinic’s Lerner Research Institute, said the study found that men who have higher levels of certain diet-related molecules are more likely to develop prostate cancer.

“As we continue our research in this area, we hope that these molecules will one day be used as early biomarkers of prostate cancer risk and help identify patients who can modify their risk of developing the disease through changes in their diet and lifestyle.”

Dr. Sharifi and his collaborators, including Dr. Stanley Hazen and Dr. Eric Klein, analyzed data from patients previously enrolled in the National Cancer Institute’s screening for prostate, lung, colon, and ovarian cancers.

The team of experts studied the basic levels of certain nutrients and metabolites (by-products produced when a substance is broken down in the intestine) in the blood of patients before they were diagnosed with prostate cancer, and compared the levels of these elements between healthy patients and those who were later diagnosed with prostate cancer and died. due to disease.

They found that men with high levels of a metabolite (intermediates and end products of metabolism) called phenylacetyl glutamine (PAGln) were two to three times more likely to develop fatal prostate cancer. This metabolite is produced when gut microbes break down phenylalanine, an amino acid found in many animal and plant protein sources, such as meat, beans and soybeans.

Choline and Betaine

The researchers also discovered that high levels of two other nutrients called choline and betaine, which are abundant in animal products such as red meat, egg yolks and high-fat dairy products, were associated with an increased risk of prostate cancer.

This is the first time that metabolites of the gut microbiome have been studied clinically in relation to prostate cancer outcomes, while these nutrients and gut metabolites have previously been studied in relation to heart disease and stroke.

Dr. Hazen was the first to identify the association of phenylacetylglutamine with an increased risk of cardiovascular disease, in the study, the results of which were published in 2020 in the journal Cell.

Dr. Hazen, MD, director of the Center for Microbiome and Human Health at the Cleveland Clinic and chair of the Division of Cardiovascular and Metabolic Sciences at the Lerner Research Institute, said it was interesting to learn that phenylacetylglutamine binds to the same metabolites as beta-blockers, which are medications commonly prescribed to help lower blood pressure. and risks of cardiovascular injuries. “This suggests that part of the efficacy of beta-blockers may be due to blocking the activity of this metabolite,” he said.

good look

Dr. Sharifi, a staff physician in the Department of Cancer Biology at the Lerner Research Institute, drew new insight into large-scale clinical data sets, which show that beta-blocker use is also associated with reduced mortality from prostate cancer, stressing the determination to continue the work. To investigate potential mechanisms linking phenylacetylglutamine activity to the mechanisms of prostate cancer, “with the hope of identifying new therapeutic targets for patients”.

The medical research team will continue to consider the reliability of the use of choline, betaine and phenylacetyl glutamine, as biomarkers of the possibility of prostate cancer, and how a change in diet can be used to modify its levels and reduce the risk of developing the disease.

Prostate cancer is a malignant tumor that begins in the prostate gland, and is different from benign prostatic hyperplasia. The risk of prostate cancer increases after the age of 65, and the risk of developing it can be reduced by eating a healthy diet with low levels of fat, and following a healthy lifestyle.

Prostate cancer is the number one cause of death among cancer types in men over the age of 75, and it is rare for men under the age of forty.

Prostate cancer occurs when a mutation occurs in the genetic material “DNA” (DNA) in the cells become abnormal, constantly grow and do not die.



Reference-www.aljazeera.net

Leave a Reply

Your email address will not be published.